Ketamine Maintenance Infusion Protocols: Frequency and Duration Optimization

Ketamine maintenance infusion protocols generally use a short induction series followed by the longest interval that continues to support a patient's response. There is no single evidence-based schedule that fits everyone. Published intravenous ketamine studies and clinical practice reports support individualized follow-up, while long-term data on frequency, tapering, and duration remain limited.

Maintenance decisions should be made with the prescribing clinician. They should account for symptom return, treatment goals, side effects, blood pressure, concurrent medicines, and the risks of repeated exposure.

What maintenance treatment is trying to achieve

Maintenance treatment aims to preserve improvement after ketamine's initial antidepressant effect. A single intravenous ketamine infusion can have a rapid effect, but that effect often fades. In a follow-up study of ketamine responders, Murrough and colleagues reported a median time to relapse of 18 days after a single infusion. Read the study record on PubMed.

That does not mean every patient needs ongoing infusions. It means the clinical team needs a plan for measuring whether benefit persists, whether intervals can be extended, and whether another treatment approach is needed. For a broader overview of treatment planning, see next steps for treatment-resistant depression.

Induction usually comes before maintenance

Many published intravenous protocols begin with repeated low-dose infusions rather than a single treatment. A commonly used research regimen is 0.5 mg/kg infused over 40 minutes, often delivered two or three times a week for several weeks. The exact number of sessions, dose, route, and setting depend on the clinician and the condition being treated.

In a randomized trial of repeated intravenous ketamine, Phillips and colleagues found higher response and remission rates with ketamine than with midazolam during the induction phase. The trial supports repeated-dose induction, but it does not establish a universal maintenance schedule. Read the trial abstract on PubMed.

If you are comparing a proposed starting schedule with a maintenance schedule, this guide on how many ketamine treatments may be needed explains the distinction.

Common maintenance scheduling approaches

Maintenance is usually individualized because durability varies substantially between people. The practical goal is not to use the most frequent schedule. It is to find the least frequent schedule that maintains a meaningful benefit with acceptable risks and burden.

Weekly treatment

Weekly sessions may be used early after induction when a patient's symptoms return quickly. This is a higher-exposure approach, so it calls for clear documentation of benefit, side effects, and the reason a longer interval is not yet appropriate.

Every two weeks

Every-two-week treatment is a commonly discussed interval in maintenance practice. It may be considered when weekly treatment appears more frequent than necessary but a monthly interval allows symptoms to return.

Every three to four weeks

Some patients can maintain improvement with longer intervals. A small published maintenance report described individually tailored intervals from weekly to monthly, with a mean interval of about three weeks. This finding is useful context, not a schedule that can be assumed to work for all patients.

Symptom-guided scheduling

Symptom-guided care uses regular rating scales and clinical review to identify early loss of benefit. It can reduce unnecessary treatment, but it may also allow partial symptom return before the next session. A patient and clinician should agree in advance on which symptoms, scores, or functional changes trigger reassessment.

For a patient-focused discussion of spacing, see how far apart low-dose ketamine treatments may be spaced.

Tapering and duration: what the evidence supports

A gradual extension of time between treatments is a reasonable way to test whether less frequent care can maintain benefit. For example, a clinician may reassess after moving from weekly to every two weeks, then consider a longer interval only after sustained stability. This is a clinical strategy, not a validated universal algorithm.

Evidence from esketamine is relevant but should not be treated as identical to intravenous racemic ketamine. Spravato is an FDA-approved esketamine nasal spray with a labeled maintenance schedule, whereas intravenous ketamine is not FDA-approved for depression. The Spravato label describes twice-weekly treatment during the first four weeks, followed by weekly or every-two-week treatment, with the least frequent dosing that maintains response.

In a maintenance-of-effect trial, Daly and colleagues reported relapse in 26.7% of participants who continued esketamine and 45.3% who switched to placebo during the 16-week maintenance phase. That result supports continued treatment for selected stable responders, but it does not answer how long intravenous ketamine maintenance should continue. Read the Daly et al. study on PubMed.

No consensus defines the total duration of intravenous ketamine maintenance. Some treatment plans use ketamine as a temporary bridge while another treatment is initiated or optimized. Others use it as an adjunct when a person has persistent symptoms despite prior care. Periodic reassessment is important because a treatment that once helped may later offer too little benefit relative to its burden or risks.

Monitoring during long-term maintenance

Monitoring makes maintenance decisions more defensible and safer. Depression severity can be tracked with a consistent validated measure such as PHQ-9, MADRS, or QIDS-SR, alongside functional changes and the patient's own account of benefit.

Clinicians commonly monitor blood pressure around infusion sessions because ketamine can raise blood pressure. They may also ask about urinary symptoms, cognition, liver-related concerns, substance use, and medication interactions. The needed tests and timing depend on the person's health history, dose, route, and duration of treatment.

Medication review matters because some medicines and substances can change safety or treatment experience. Read about ketamine drug interactions and ketamine and alcohol safety considerations before assuming a maintenance plan is appropriate.

Can psychotherapy help maintenance last longer?

Psychotherapy may be part of a broader treatment plan, but evidence has not yet established a specific therapy timing or method that reliably extends the effect of maintenance infusions. The idea that ketamine-related plasticity could support therapeutic learning is biologically plausible, yet it remains a research question in maintenance care. Learn more about ketamine integration therapy and the limits of current evidence.

Bottom line

The most supportable approach is individualized maintenance at the longest effective interval, with regular measurement of mood, function, and adverse effects. Weekly, biweekly, and monthly schedules all appear in clinical practice and research reports, but none is a default answer for every patient. A clear tapering plan and a plan for recurrence are as important as the infusion frequency itself.